TEMPEST THERAPEUTICS INC NASDAQ:TPST Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARa, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX-1 designed to activate the cGAS/STING pathway selectively. Tempest is headquartered in South San Francisco and supported by notable healthcare investors.

Location: 110 Miller Ave Ste 100, Michigan, 48104-1305, United States | Website: www.tempesttx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing